{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:01:57Z","timestamp":1793581317174,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.radonc.2025.111280","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T07:05:05Z","timestamp":1763276705000},"page":"111280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Survival outcomes and toxicity profile after CT-guided HDR brachytherapy (interventional radiotherapy) for liver oligometastases in breast cancer patients: The BRALIBREST real world multicenter study"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-3028","authenticated-orcid":false,"given":"Mateusz","family":"Bilski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-269X","authenticated-orcid":false,"given":"\u0141ukasz","family":"Kuncman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8301-8059","authenticated-orcid":false,"given":"Magdalena","family":"Orzechowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-5289","authenticated-orcid":false,"given":"Pawe\u0142","family":"Cisek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mastroleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miko\u0142aj","family":"Skrzypczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4477-412X","authenticated-orcid":false,"given":"Sylwia","family":"Sroka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6376-1886","authenticated-orcid":false,"given":"Ewa","family":"Wojtyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1391-6600","authenticated-orcid":false,"given":"Konstantinos","family":"Ferentinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4438-892X","authenticated-orcid":false,"given":"Kathrin","family":"Hering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Fijuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8151-3673","authenticated-orcid":false,"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6336-5674","authenticated-orcid":false,"given":"Hai Minh","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Medenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3471-4701","authenticated-orcid":false,"given":"Matthias P.","family":"Fabritius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8709-7252","authenticated-orcid":false,"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-5410","authenticated-orcid":false,"given":"Max","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Pech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3351-8896","authenticated-orcid":false,"given":"Paul","family":"Rogowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111280_b0005","doi-asserted-by":"crossref","unstructured":"Miglietta F, Visani L, Marini S, Griguolo G, Vernaci GM, Bottosso M, Dieci MV, Meattini I, Guarneri V. Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? Cancer Treat Rev. 2022 Nov;110:102462. doi: 10.1016\/j.ctrv.2022.102462. Epub 2022 Sep 6. PMID: 36087503.","DOI":"10.1016\/j.ctrv.2022.102462"},{"key":"10.1016\/j.radonc.2025.111280_b0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/jwas.jwas_16_24","article-title":"Does hepatic metastasectomy for breast cancer oligo- metastasis to the liver offer survival advantage? Systematic review and meta-analysis","volume":"15","author":"Garzali","year":"2025","journal-title":"J West Afr Coll Surg"},{"key":"10.1016\/j.radonc.2025.111280_b0015","doi-asserted-by":"crossref","unstructured":"Dorn PL, Meriwether A, LeMieux M, Weichselbaum RR, Chmura SJ, Hasan Y: Patterns of distant failure and progression in breast cancer: implications for the treatment of oligometastatic disease. Int J Radiat Oncol Biol Phys. 2011, 81:10.1016\/j.ijrobp.2011.06.1901.","DOI":"10.1016\/j.ijrobp.2011.06.1901"},{"key":"10.1016\/j.radonc.2025.111280_b0020","article-title":"De novo and recurrent metastatic breast cancer - a systematic review of population-level changes in survival since 1995","volume":"29","author":"Lord","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.radonc.2025.111280_b0025","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111280_b0030","unstructured":"NRG-BR002: phase IIR\/III trial of standard of care systemic therapy with or without SBRT and\/or surgical resection for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol, 10.1200\/JCO.2022.40.16-supply.1007."},{"key":"10.1016\/j.radonc.2025.111280_b0035","author":"Tsai","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111280_b0040","doi-asserted-by":"crossref","unstructured":"Reddy JP, Sherry AD, Fellman B, Liu S, Bathala T, Haymaker C, Cohen L, Smith BD, Ramirez D, Shaitelman SF, Chun SG, Medina-Rosales M, Teshome M, Brewster A, Barcenas CH, Reuben A, Ghia AJ, Ludmir EB, Weed D, Shah SJ, Mitchell MP, Woodward WA, Gomez DR, Tang C. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2025 Mar 15;121(4):885-893. doi: 10.1016\/j.ijrobp.2024.10.030. Epub 2024 Oct 30. PMID: 39486645; PMCID: PMC11850186.","DOI":"10.1016\/j.ijrobp.2024.10.030"},{"key":"10.1016\/j.radonc.2025.111280_b0050","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.21037\/apm-20-1128","article-title":"Oligometastatic breast cancer: where are we now and where are we headed?\u2014a narrative review","volume":"10","author":"Kent","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.radonc.2025.111280_b0055","doi-asserted-by":"crossref","unstructured":"Rangarajan K, Lazzereschi L, Votano D, Hamady Z. Breast cancer liver metastases: systematic review and time to event meta-analysis with comparison between available treatments. Ann R Coll Surg Engl. 2023 Apr;105(4):293-305. doi: 10.1308\/rcsann.2021.0308. Epub 2022 Feb 17. PMID: 35175853; PMCID: PMC10066639.","DOI":"10.1308\/rcsann.2021.0308"},{"key":"10.1016\/j.radonc.2025.111280_b0060","doi-asserted-by":"crossref","unstructured":"Zou X, Zou HL, Luo X, Chen XW, Huang WL, Zhang C, Ren G, Huang JH, Han X, Jiang YQ. Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status. Breast. 2025 Feb;79:103876. doi: 10.1016\/j.breast.2025.103876. Epub 2025 Jan 8. PMID: 39808955; PMCID: PMC11782866.","DOI":"10.1016\/j.breast.2025.103876"},{"key":"10.1016\/j.radonc.2025.111280_b0065","doi-asserted-by":"crossref","unstructured":"Bilski M, Korab K, Orzechowska M, Ponikowska J, Cisek P, Jereczek-Fossa BA, Fijuth J, Kuncman \u0141. Comprehensive cohort study: computer tomography-guided high-dose rate brachytherapy as metastasis-directed therapy for liver metastases from colorectal cancer in repeat oligoprogression. Radiol Med. 2025 May;130(5):694-705. doi: 10.1007\/s11547-025-01988-y. Epub 2025 Mar 13. PMID: 40080327; PMCID: PMC12106498.","DOI":"10.1007\/s11547-025-01988-y"},{"key":"10.1016\/j.radonc.2025.111280_b0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10585-025-10348-z","article-title":"EORTC\/ESTRO defined induced oligopersistence of liver metastases from colorectal cancer - outcomes and toxicity profile of computer tomography guided high-dose-rate brachytherapy","volume":"42","author":"Cisek","year":"2025","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.radonc.2025.111280_b0075","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.3390\/cancers13246250","article-title":"Interstitial high-dose-rate brachytherapy of liver metastases in oligometastatic patients","volume":"13","author":"Walter","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111280_b0080","article-title":"HDR brachytherapy versus robotic-based and linac-based stereotactic ablative body radiotherapy in the treatment of liver metastases - a dosimetric comparison study of three radioablative techniques","volume":"3","author":"Bilski","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111280_b0085","article-title":"Radiotherapy as a metastasis directed therapy for liver oligometastases - comparative analysis between CT-guided interstitial HDR brachytherapy and two SBRT modalities performed on double-layer and single layer LINACs","volume":"4","author":"Bilski","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.111280_b0090","article-title":"A dosimetric comparison of different radiotherapy modalities for non-resected oligometastatic liver disease","volume":"13","author":"Dejonckheere","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111280_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2019.05.023","article-title":"Bednarek a K evaluate cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator","author":"Og\u0142uszka","year":"2019","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.radonc.2025.111280_b0100","doi-asserted-by":"crossref","unstructured":"Waninger JJ, Ma VT, Chopra Z, Pearson AN, Green MD. Evaluation of the prognostic role of liver metastases on patient outcomes: systematic review and meta-analysis. Cancer J. 2023 Sep-Oct 01;29(5):279-284. doi: 10.1097\/PPO.0000000000000683. PMID: 37796646; PMCID: PMC10558088.","DOI":"10.1097\/PPO.0000000000000683"},{"key":"10.1016\/j.radonc.2025.111280_b0105","article-title":"SABR-COMET-10: a randomized phase III trial of stereotactic ablative radiotherapy for patients with 4\u201310 oligometastatic tumors","author":"Palma","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111280_b0110","doi-asserted-by":"crossref","unstructured":"Zou X, Zou HL, Luo X, Chen XW, Huang WL, Zhang C, Ren G, Huang JH, Han X, Jiang YQ. Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status. Breast. 2025 Feb;79:103876. doi: 10.1016\/j.breast.2025.103876. Epub 2025 Jan 8. PMID: 39808955; PMCID: PMC11782866.","DOI":"10.1016\/j.breast.2025.103876"},{"key":"10.1016\/j.radonc.2025.111280_b0115","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jvir.2012.01.079","article-title":"Percutaneous computed tomography-guided high-dose-rate brachytherapy ablation of breast cancer liver metastases: initial experience with 80 lesions","volume":"23","author":"Collettini","year":"2012","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.radonc.2025.111280_b0120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.radonc.2011.03.005","article-title":"Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy - a phase II-study","volume":"100","author":"Wieners","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111280_b0125","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12885-015-1499-z","article-title":"Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)","volume":"14","author":"Seidensticker","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2025.111280_b0130","doi-asserted-by":"crossref","unstructured":"Rangarajan K, Lazzereschi L, Votano D, Hamady Z. Breast cancer liver metastases: systematic review and time to event meta-analysis with comparison between available treatments. Ann R Coll Surg Engl. 2023 Apr;105(4):293-305. doi: 10.1308\/rcsann.2021.0308. Epub 2022 Feb 17. PMID: 35175853; PMCID: PMC10066639.","DOI":"10.1308\/rcsann.2021.0308"},{"key":"10.1016\/j.radonc.2025.111280_b0135","doi-asserted-by":"crossref","unstructured":"Garzali IU, Sheshe AA, Suleiman IE, El-Yakub AI, Abu Zeid EED. Does Hepatic Metastasectomy for Breast Cancer Oligo-Metastasis to the Liver Offer Survival Advantage? Systematic Review and Meta-Analysis. J West Afr Coll Surg. 2025 Apr-Jun;15(2):129-135. doi: 10.4103\/jwas.jwas_16_24. Epub 2024 Sep 2. PMID: 40094128; PMCID: PMC11908727.","DOI":"10.4103\/jwas.jwas_16_24"},{"key":"10.1016\/j.radonc.2025.111280_b0140","article-title":"A systematic review of thesurgi-caland ablative management of breast cancer liver metastasis","author":"Yoon-Flannery","year":"2018","journal-title":"Adv Breast Cancer Ther"},{"key":"10.1016\/j.radonc.2025.111280_b0150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.breast.2018.09.006","article-title":"Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy","volume":"42","author":"Onal","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2025.111280_b0155","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clbc.2020.05.006","article-title":"Liver metastases-directed therapy in the management of oligometastatic breast cancer","volume":"20","author":"Franzese","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.radonc.2025.111280_b0160","first-page":"180","article-title":"CT texture analysis of response to liver metastases ablation: correlation with pathologic response and radiomics potential","volume":"307","author":"Lubner","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.radonc.2025.111280_b0175","first-page":"1671","article-title":"Stereotactic radiosurgery for multiple brain metastases: a retrospective multi-institutional analysis","volume":"41","author":"Yamamoto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111280_b0180","first-page":"165","article-title":"Outcomes and selection criteria of liver-directed therapy in polymetastatic breast cancer: insights from the SABR-BREAST registry","volume":"36","author":"Aitken","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.111280_b0185","doi-asserted-by":"crossref","first-page":"22735","DOI":"10.1038\/s41598-025-09227-0","article-title":"Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases","volume":"15","author":"Cisek","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.111280_b0190","first-page":"34","article-title":"Biochemical liver function markers after CT-guided brachytherapy for liver metastases","volume":"11","author":"Cisek","year":"2017","journal-title":"Onkol i Radioter"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:22:10Z","timestamp":1786537330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025052843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"alternative-id":["S0167814025052843"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111280","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes and toxicity profile after CT-guided HDR brachytherapy (interventional radiotherapy) for liver oligometastases in breast cancer patients: The BRALIBREST real world multicenter study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111280"}}